The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting

Bassand, 2007, The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes, Eur Heart J, 28, 1598, 10.1093/eurheartj/ehm161 Schreiner, 2007, Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed, Crit Pathw Cardiol, 6, 169, 10.1097/HPC.0b013e318159921e Bhatt, 2008, ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents, Circulation, 118, 1894, 10.1161/CIRCULATIONAHA.108.191087 Grossmann, 2004, Variable extent of clopidogrel responsiveness in patients after coronary stenting, Thromb Haemost, 92, 1201, 10.1160/TH04-01-0049 Gurbel, 2006, Drug insight: Clopidogrel nonresponsiveness, Nat Clin Pract Cardiovasc Med, 3, 387, 10.1038/ncpcardio0602 Lev, 2006, Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: The role of dual drug resistance, J Am Coll Cardiol, 47, 27, 10.1016/j.jacc.2005.08.058 Lau, 2004, Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance, Circulation, 109, 166, 10.1161/01.CIR.0000112378.09325.F9 Farid, 2007, Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently, Clin Pharmacol Ther, 81, 735, 10.1038/sj.clpt.6100139 Suh, 2006, Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel, Can Med Assoc J, 174, 1715, 10.1503/cmaj.060664 Gilard, 2008, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study, J Am Coll Cardiol, 51, 256, 10.1016/j.jacc.2007.06.064 Foussas, 2007, The impact of oral antiplatelet responsiveness on the long-term prognosis after coronary stenting, Am Heart J, 154, 676, 10.1016/j.ahj.2007.06.013 Juurlink, 2009, A population-based study of the drug interaction between proton pump inhibitors and clopidogrel, CMAJ, 180, 713, 10.1503/cmaj.082001 Ho, 2009, Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome, JAMA, 301, 937, 10.1001/jama.2009.261 Savi, 1994, The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A, Thromb Haemost, 72, 313, 10.1055/s-0038-1648859 Hulot, 2006, Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects, Blood, 108, 2244, 10.1182/blood-2006-04-013052 Lau, 2003, Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drugdrug interaction, Circulation, 107, 32, 10.1161/01.CIR.0000047060.60595.CC Lotfi, 2008, Am Heart J, 155, 954, 10.1016/j.ahj.2007.12.009 Trenk, 2008, Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement, Thromb Haemost, 99, 174, 10.1160/TH07-08-0503 Saw, 2007, CHARISMA Investigators. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial, J Am Coll Cardiol, 50, 291, 10.1016/j.jacc.2007.01.097